Active	Status	Sponsor type	Region	Phase	Filter
2 Active 1 Inactive 3 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes: « April » « 2025 » M T W T F S S 31 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 1 2 3 4   - « April » « 2025 » M T W T F S S 31 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 1 2 3 4   Show only changed items Enrollment:

Advanced Filters

2 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Kim, Sang-Heon
NCT06372496: Pragmatic Open - Label Randomized Clinical Trial of FF/UMEC/VI vs Non-ellipta Usual Care ICS-LABA for Adult Participants With Uncontrolled Asthma	Active, not recruiting	4	1358	Canada, Japan, US, RoW	Fluticasone furoate/umeclidinium bromide/vilanterol trifenatate, Inhaled corticosteroids/long-acting beta-2 agonists	GlaxoSmithKline	Asthma	11/25	03/26
NCT05544942: GCWB1001 Evaluates the Effectiveness and Safety of Respiratory Health	Recruiting	N/A	120	RoW	Lactobacillus plantarum, maltodextrin	Green Cross Wellbeing	Respiratory Symptoms	03/23	05/23

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Kim, Sang-Heon
NCT06372496: Pragmatic Open - Label Randomized Clinical Trial of FF/UMEC/VI vs Non-ellipta Usual Care ICS-LABA for Adult Participants With Uncontrolled Asthma	Active, not recruiting	4	1358	Canada, Japan, US, RoW	Fluticasone furoate/umeclidinium bromide/vilanterol trifenatate, Inhaled corticosteroids/long-acting beta-2 agonists	GlaxoSmithKline	Asthma	11/25	03/26
NCT05544942: GCWB1001 Evaluates the Effectiveness and Safety of Respiratory Health	Recruiting	N/A	120	RoW	Lactobacillus plantarum, maltodextrin	Green Cross Wellbeing	Respiratory Symptoms	03/23	05/23